Oncology Central

Approval granted for novel non-small cell lung cancer drug

0
The FDA has granted approval for Imfinzi®, one of AstraZeneca’s (Cambridge, UK) novel key therapeutic agents, making it the only immunotherapy approved for unresectable Stage III non-small cell lung cancer (NSCLC).
Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.

Share:

Insights

Videos

News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.